FDA approves vaccine for Ebola clinical trials Print
By Ghana News Agency   
Sunday, 15 November 2015 15:32

The Food and Drugs Authority (FDA) has approved a vaccine, namely the

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

Johnson Ebola vaccine for clinical trials as part of international effort to find a cure to deadly Ebola Virus Disease (EVD).  A second vaccine, the GSK vaccine, is currently being considered for approval.

 

The Food and Drugs Authority (FDA) has approved a vaccine, namely the Johnson Ebola vaccine for clinical trials as part of international effort to find a cure to deadly Ebola Virus Disease (EVD).

A second vaccine, the GSK vaccine, is currently being considered for approval.

This information was contained in a report of the Parliamentary Committee on Health on the “Ebola Vaccination Trials in the Country”, presented to the plenary in Accra on Thursday.

The Committee, cognisant of the fact that approval has been given in order for the trial to be carried out, recommended to the House to urge the Minister for Health to intensify education on the clinical trials.

Presenting the Report, presented by Dr Richard Winfred Anane, Ranking Member of the Committee noted that after interaction with key stakeholders, the Committee was persuaded that there had not been Ebola clinical trial going on in the country.

“The Committee was convinced that the vaccine approved for the clinical trial is safe and that most of the concerns about the vaccine can only be answered after the clinical trials have been taken,” the Report noted.

It added: “Indeed, it is because of these concerns that this scientific exercise is being take with the view of coming out with a cure for the dreaded EVD. The trials are to be conducted with the strictest adherence to national regulations and international standards. There is a constant review mechanism both at the national and international level.”

The report noted the proximity of Ghana to Ebola affected nations, which makes it susceptible to an EVD, and cautioned that in the event of any outbreak, the impact could be disastrous.

“There is therefore the need for the country to hold itself in readiness, especially if it can help find a cure in any eventuality,” is said.

   

   

   


READ MORE HERE 







BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1